Latest stories

Ribo Files EU Clinical Trial Application for Dual-Targeting siRNA SR122 in Dyslipidemia

Ribo Files EU Clinical Trial Application for Dual-Targeting siRNA SR122 in Dyslipidemia

Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals have submitted a Phase I clinical trial application in the EU for SR122, a dual GalNAc conjugated siRNA targeting ApoC3 and PCSK9 for dyslipidemia. The randomized, placebo-controlled study will assess safety, tolerability, pharmacokinetics and pharmacodynamics in healthy participants.

MoleculeMind report details MMDesign results across nanobodies and macrocyclic peptides

MoleculeMind report details MMDesign results across nanobodies and macrocyclic peptides

MoleculeMind has released a technical report on MMDesign, its AI-powered de novo molecular design platform, citing a 94.7% campaign success rate across 19 design campaigns spanning 18 targets and two molecular modalities. The report also compares its MMFold structure prediction model with AlphaFold 3 on the FoldBench benchmark.